Cytosorbents Corporation (CTSO)
| Market Cap | 9.64M -83.5% |
| Revenue (ttm) | 37.22M +3.1% |
| Net Income | -18.21M |
| EPS | -5.82 |
| Shares Out | 3.15M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,741 |
| Open | 2.955 |
| Previous Close | 3.090 |
| Day's Range | 2.840 - 3.090 |
| 52-Week Range | 2.840 - 18.800 |
| Beta | 1.37 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 12, 2026 |
About CTSO
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammator... [Read more]
Financial Performance
In 2025, Cytosorbents's revenue was $37.06 million, an increase of 4.12% compared to the previous year's $35.60 million. Losses were -$8.20 million, -60.43% less than in 2024.
Financial StatementsNews
CytoSorbents Announces New Data Presentations at Upcoming International Conferences in Cardiac Surgery and Critical Care
PRINCETON, N.J., Sept. 30, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using b...
CytoSorbents Regains Compliance with Nasdaq Minimum Bid Price Requirement
PRINCETON, N.J., Sept. 23, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using b...
Cytosorbents Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The company is advancing blood purification technologies, with strong international sales and improving gross margins. Restructuring in Germany is showing early benefits, and a new Dubai subsidiary targets MENA growth. DrugSorb-ATR is progressing toward FDA submission, supported by robust clinical and real-world data.
CytoSorbents to Present at the H.C. Wainwright 28th Annual Global Investment Conference
PRINCETON, N.J., Sept. 10, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using b...
CytoSorbents trading halted, news pending
19:50 EDT CytoSorbents (CTSO) trading halted, news pending
CytoSorbents to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference
Princeton, New Jersey--(Newsfile Corp. - September 4, 2026) - CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac s...
CytoSorbents announces 1-for-20 reverse stock split
CytoSorbents (CTSO) Corporation announced that it will effect a one-for-twenty reverse stock split of its common stock, par value $0.001 per share. The Reverse Stock Split is expected to become…
CytoSorbents Announces Reverse Stock Split
Reverse Stock Split Previously Approved by Shareholders; Intended to Support Compliance with Nasdaq's $1.00 Minimum Bid Price Requirement Expected to Become Effective and Trade on Split-Adjusted Basis...
CytoSorbents announces real-world data using CytoSorb
CytoSorbents (CTSO) announced an independent new patient-level matched analysis of real-world data demonstrating that intraoperative use of CytoSorb was associated with a significant reduction in seve...
CytoSorbents Announces New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor and Updates Recent DrugSorb-ATR FDA Pre-Submission Meetings
Patient-level matched analysis of real-world data demonstrated a significant 37% relative reduction in severe bleeding Significant reductions in 24-hour chest tube drainage and red blood cell transfus...
Cytosorbents Transcript: AGM 2026
The meeting confirmed quorum, approved all proposals, and outlined four strategic priorities: achieving cash flow breakeven, returning core business to growth, advancing U.S. regulatory approval for DrugSorb-ATR, and unlocking HemoDefend-BGA value. Financial performance improved with higher margins and reduced losses, while management addressed shareholder concerns about trust and cost controls.
Cytosorbents Slides: Investor presentation
Cytosorbents has posted slides in relation to its latest quarterly earnings report, which was published on August 11, 2026.
Cytosorbents Earnings Call Transcript: Q2 2026
Revenue held steady at $9.6M with gross margins rising to 73% and operating cash burn reduced to $200K. Progress continues toward cash flow breakeven, while regulatory and commercial initiatives advance for DrugSorb-ATR and HemoDefend-BGA.
Cytosorbents Quarterly report: Q2 2026
Cytosorbents has published its Q2 2026 quarterly earnings report on August 6, 2026.
Cytosorbents Earnings release: Q2 2026
Cytosorbents released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Cytosorbents Slides: Q2 2026
Cytosorbents has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update
Highlighting Four Independent Drivers of Shareholder Value PRINCETON, N.J., Aug. 6, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditio...
CytoSorbents to Report Second Quarter 2026 Financial Results and Recent Business Highlights
PRINCETON, N.J., July 20, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using bl...
Cytosorbents Proxy statement: Proxy filing
Cytosorbents filed a proxy statement on June 25, 2026, providing details for shareholder voting and corporate governance matters.
Cytosorbents Proxy statement: Proxy filing
Cytosorbents filed a proxy statement on June 25, 2026, providing details for shareholder voting and corporate governance matters.
Cytosorbents Transcript: Life Sciences Virtual Investor Forum
CytoSorbents presented its established blood purification business, highlighting strong international sales, high gross margins, and a robust product pipeline. Regulatory progress for DrugSorb-ATR in North America is advancing, with FDA submissions planned for late 2026 and a focus on expanding market opportunities in critical care and cardiac surgery.
Cytosorbents Slides: Life Sciences Virtual Investor Forum
Cytosorbents has posted slides in relation to its latest quarterly earnings report, which was published on June 24, 2026.
CytoSorbents to Present at the Life Sciences Forum on June 24, 2026 and Meet Virtually with Investors on June 30, 2026
PRINCETON, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery usin...
Cytosorbents Proxy statement: Proxy filing
Cytosorbents filed a proxy statement on June 11, 2026, providing details for shareholder voting and corporate governance matters.
CytoSorbents reports Q1 adjusted EPS (5c) vs. (6c) last year
Reports Q1 revenue $8.9M vs. $8.7M last year. “First quarter sales were $8.9 million, driven by 13% growth in our direct sales territories outside of Germany,” stated Dr. Phillip Chan,…